President - Psychedelic Medicine Association
Dr. Ingmar Gorman, Co-Founder and Chief Executive Officer of Fluence, is a distinguished psychologist specializing in psychedelic treatments. His clinical training was undertaken in New York City's esteemed institutions, including Columbia University and Bellevue Hospital. Following this, he completed an NIH postdoctoral fellowship at New York University. Dr. Gorman's contributions to the field extend to significant research roles, such as co-principal investigator on a Phase 3 clinical trial examining MDMA-assisted psychotherapy for PTSD. As an accomplished scholar, Dr. Gorman has published extensively on subjects like classic psychedelics, ketamine, MDMA, and Psychedelic Harm Reduction and Integration. His work embodies a commitment to advancing the understanding and application of psychedelic treatments in mental health.
Co-Founder and Clinical Director, Alchemy Community Therapy Center
Irina is a therapist who loves people who use drugs, people who live on the edges of society, and people whose existence is a radical act in and of itself. She is one of the original co-founders of Alchemy, finding passion in the intersections of community mental health, harm reduction, and psychedelic therapy. She’s worked for over a decade doing street-based outreach work, which she continues to do in San Francisco. Irina has volunteered for several years with the Zendo Project and is currently also working as an Adherence Rater in the MAPS MDMA Clinical Trials. In her spare time, she enjoys playing with her dog Zaychik, taking photos of her poison dart frogs, and watching the newest queer tv series.
Clinical Psychologist, Lead Trainer and Co-founder, Polaris Insight Center
Eric Sienknecht, Psy.D., is a Co-founder, Clinical Psychologist, and Lead Trainer at Polaris Insight Center, a ketamine-assisted psychotherapy clinic and training center in San Francisco. He earned his doctorate in Clinical Psychology from California Institute of Integral Studies (CIIS) and has undergone training in psychedelic psychotherapy with the Ketamine Training Center (KTC) and Multidisciplinary Association of Psychedelic Studies (MAPS). He is currently a Supervisor on the Clinical Trials of MDMA-AT for PTSD and Educator with MAPS/MPBC. His professional interests include the phenomenology of non-ordinary states of consciousness, the role of mystical experiences in therapeutic outcomes, music in psychedelic psychotherapy, psychoanalysis, mindfulness, and developing and refining psychedelic therapy training curricula.
As psychedelics become more integrated into the medical mainstream, we know that practitioners of every type may be interested in how they can get more involved. At the most basic level, clinicians can simply get informed about psychedelics and share their knowledge with patients. However, we know that once clinicians learn about how effective and transformative psychedelic therapies can be, they often want to get more involved.
For example, many members ask in our forums what paths are best to begin working with psychedelics as a psychedelic-assisted therapist or facilitator. We also get a lot of specific questions about which training programs members should check out.
In order to help answer some of those questions, we are going to start focusing some of our monthly webinars on the topic of training programs and other topics that would help members who desire to get more involved in psychedelic therapies.
This month we have representatives from training programs answering the following questions:
…and much more!
As always, there will be ample time for audience Q & A, so you’ll get to interact with the panelists directly!
So please join us for this live panel discussion on Thursday, May 25th at 5 pm Pacific, 8 pm Eastern. This is exclusively for members of the Psychedelic Medicine Association, so if you have not yet registered, please do so here. A link to the recording will be available afterward if you cannot make it to the live event.Hope to see you all on the 25th!
You can find the Psychedelic Medicine Association on Twitter, LinkedIn, and on Facebook.
There was a problem reporting this post.
Please confirm you want to block this member.
You will no longer be able to:
Please allow a few minutes for this process to complete.